Shots:
- Adaptive has entered into 2 non-exclusive agreements with Pfizer, combining its T-cell receptor (TCR) discovery & immune receptor antigen-mapping platform to support Pfizer’s research across autoimmune & other disease areas
- As per the target discovery deal, Adaptive will identify disease-specific TCR targets in rheumatoid arthritis from Pfizer clinical samples, while Pfizer will lead development & commercialization of potential therapies, with Adaptive receiving upfront & milestone payments totaling ~$890M
- As per the data licensing deal, Pfizer licensed Adaptive’s TCR-antigen dataset to train its AI/ML models for drug discovery across multiple diseases, with Adaptive receiving upfront & annual licensing fees under this non-exclusive, multi-year deal. Specific financial terms remain undisclosed
Ref: Adaptive| Image: Adaptive & Pfizer |Press Release
Related News: Pfizer Collaborates with YaoPharma in a ~$2.1B Licensing Deal for YP05002
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
